Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

(APRI)

(APRI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

11975 EL CAMINO REAL SUITE 300 SAN DIEGO CA 92130 USA

www.apricusbio.com P: 858-222-8041

Description:

Apricus Bio operates in the pharmaceutical industry and focuses on research and development in the area of drug delivery. Its proprietary drug delivery technology is called NexACT '. Backed by revenue generating CRO business, Bio-Quant, Inc. and its NexMed USA subsidiary, Apricus Bio has leveraged the flexibility of its proven NexACT' drug delivery technology to enable multi-route administration of new and improved compounds across numerous therapeutic classes. The Company is seeking to monetize its existing product pipeline, including compounds from pre-clinical through Phase 3, currently focused on dermatology, sexual dysfunction and cancer. Apricus Bio was formerly known as NexMed, Inc and is headquartered in San Diago, California.

Key Statistics

Overview:

Market Capitalization, $K 6,197
Shares Outstanding, K 28,167
Annual Sales, $ 394 K
Annual Net Income, $ 320 K
60-Month Beta 1.20
% of Insider Shareholders 2.32%
% of Institutional Shareholders 19.89%

Growth:

1-Year Return -4.35%
3-Year Return 0.00%
5-Year Return 0.00%
5-Year Revenue Growth -100.00%
5-Year Earnings Growth 82.93%
5-Year Dividend Growth 0.00%

Per-Share Information:

Latest Earnings Date 03/07/19
Earnings Per Share ttm -0.36
EPS Growth vs. Prev Qtr -20.00%
EPS Growth vs. Prev Year 60.00%
Annual Dividend Rate, $ 0.00
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%

APRI Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -216.45%
Return-on-Assets % -153.13%
Profit Margin % -7,165.23%
Debt/Equity N/A
Price/Sales N/A
Price/Cash Flow N/A
Price/Book 1.79
Book Value/Share 0.00
Interest Coverage -145.88
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar